Clinical Trial Update: A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, efficacy, and tolerability of Sativex for spasticity in children with cerebral palsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Palsy

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Cerebral Palsy | Phase 3 | Status: COMPLETED